Viatris
VTRS
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
PRNewsWire • 13 days ago • VTRS
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
PRNewsWire • 25 days ago • VTRS
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Zacks Investment Research • 26 days ago • VTRS
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?
GlobeNewsWire • 27 days ago • VTRS
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
Zacks Investment Research • about a month ago • VTRS
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.